About
Technology
Issues
FAQ
Links
Official Page
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.